Life Technologies News & Views

Life Technologies Received IR Global Rankings Honors

2010-04-22T19:26:00.000-07:00

Life Technologies was awarded “Best Corporate Governance in the Health Care Industry” and rated among the “Top 5 Corporate Governance in North America” for 2010, as announced by Investor Relations Global Rankings (IRGR) on April 6. IRGR is the most comprehensive auditing and ranking system for investor relations websites, corporate governance practices and financial disclosure procedures.

More than 500 companies from over 30 countries were evaluated, and Life Technologies was ranked against 53 others in our area. The award takes into consideration remuneration and performance, board accountability, capital structure, shareholder protection, shareholder meetings, internal control mechanisms, financial statements and disclosure.

Life Technologies Highlights Genomic Analysis Technologies at 101st Annual Meeting of the American Association For Cancer Research

2010-04-16T11:26:00.000-07:00

WASHINGTON, DC, April 16, 2010 – Life Technologies’ genomic sequencing and analysis products and a number of presentations specific to oncology research, will be presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR). The meeting is taking place Saturday, April 17 through Wednesday, April 21 at the Walter E. Washington Convention Center in Washington, DC.

During the AACR conference, Life Technologies will emphasize its commitment to cancer research with multiple presentations, including the commercial release of the research-use-only (RUO) KRAS and BRAF Mutation Analysis Reagents under the Life Technologies brand, Applied Biosystems®. The reagent sets can be analyzed using the 3500 Series Genetic Analyzer.

Work conducted by a team led by Howard Doong, Ph.D, of TrimGen Corporation will present results of Life Technologies’ new KRAF and BRAF mutation analysis reagent sets at a late-breaker poster session on Tuesday, April 20 from 9 a.m. to noon. Using these reagent sets for KRAS analysis, Dr. Doong will report on his study comparing KRAS mutations observed in 118 formalin-fixed paraffin-embedded tumor samples. Mutations in KRAS and BRAF oncogenes have been implicated to have an association with certain cancer treatments.

In addition, several abstracts and papers using the SOLiD 4 System will be presented at the meeting, including a presentation by Dr. Victor E. Velculescu of The Johns Hopkins Oncology Center. Dr. Velculescu is using the system to identify personalized biomarkers for solid tumors.

This approach may one day provide broadly applicable improvements to the clinical management of cancer patients. The high accuracy of the SOLiD 4 System is critical in discovery of rare variants in heterogeneous tumor samples.

Life Technologies’ at AACR Breakout Sessions

AACR presentations demonstrate the broad utility, superior accuracy and reliability of Life Technologies’ tools across multiple generations of genetic sequencing and analysis technology – qualities that are important to oncology research from discovery to the clinic. These presentations include:

Saturday, April 17
• Conference Session #MW12: “Next-Generation Sequencing: Data Analysis and Applications”
3:15 p.m. – 5:15 p.m., Room 145
Chairperson: Dr. Victor Velculescu, John Hopkins Oncology Center
• Conference Session #MW12: “SOLiD Sequencing With Error Correction Codes: In Pursuit of Somatic Mutation Detection”
3:45 p.m. – 4:05 p.m., Room 145
Presenter: Kevin McKernan, Life Technologies

Monday, April 19
• Poster # 2212/1: “A Genomic Portrait of Tumor Progression Using Next Generation Sequencing”
2:00 p.m. – 5:00 p.m., Exhibit Hall A-C, Poster Section 10
Presenter: Dr. Jun S. Wei, National Cancer Institute
• Presentation #2196: “Genome-Wide Analysis of DNA Methylation Patterns in Formaldehyde-Fixed Paraffin-Embedded (FFPE) Human Tumor Specimens”
2:00 p.m. – 5:00 p.m., Exhibit Hall A-C, Poster Section 9, Board #15
Presenter: Dr. Fabienne Brenet, Weill-Cornell College

Tuesday, April 20
• Presentation #2957: “Characterization of Oral Tumors by Massively Parallel Litgation Sequencing”
9:00 a.m. – Noon, Exhibit Hall A-C, Poster Section 1, Board #18
Presenter: Dr. Rebecca R. Laborde, Mayo Clinic
• Poster # 2117/8: “Identification of Rare KRAS Mutations in Codons 12 and 13 by Shifted Termination Assay,” Late-Breaking Research: Clinical Research 2.
9.00 am – Noon, Exhibit Hall A-C, Poster Section 40. Abstract number: LB-222.
Presenter: Julian Walker, Life Technologies

For more information on our technologies, please stop by our booth #534.

About Life Technologies (www.lifetechnologies.com)
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit us online at www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

For Research Use Only. Not for use in diagnostic procedures.

Life Technologies Contact
Patty Zamora
760.476.7818
patty.zamora@lifetech.com
or
Heather Platisha
415.637.8025
heather.platisha@edelman.com

Science in the Classroom

2010-04-16T11:18:00.000-07:00

Mother Teresa Catholic Elementary School is proud to announce the donation of a 310 DNA Analyzer by Life Technologies Corporation, which will be used in the school’s science laboratory.

The analyzer was donated to the school by Life Technologies, at the request of MTCES parent Gregory LaCrosse, a regional specialist in Molecular Biology for the company. LaCrosse sought the donation as part of an effort to encourage and foster interest in science at the grade school level.

“As educators, we are always looking for new ways to encourage and excite children academically,” remarked Sister Anne, MTCES Principal. “Greg LaCrosse and his wife Julie are among a group of parents working to show students how science plays an important role in everyday life. The addition of the DNA Analyzer to our science lab, coupled with the innovative programs and presentations planned by our parents and teachers, will have a long-term positive impact on our students.”

LaCrosse added, “We hope to get other schools to visit and use our lab. My long term hope is that this idea spreads to other dioceses and districts, resulting in more people becoming interested in science.”

Mother Teresa Elementary School, an independent Catholic school serving families of kindergarten through eighth grade children, is located at 7197 Mother Teresa Lane (formerly 6085 Jackie Drive) in Liberty Township.

Making Cells to Grow Sales - Expanding the GIBCO Footprint

2010-04-16T09:28:00.000-07:00

While GIBCO has been known for almost 50 years as an industry leader for cell culture media, the move upstream into the creation of recombinant CHO cell lines is a more recent shift in product strategy. Beginning in 2009 with the launch of Life Technologies first integrated cell line kit (OptiCHO Protein Express), the strategy of creating platforms for biotherapeutic production has become a focus for the Grand Island, Bedford, and Frederick R&D teams. In line with this expanded R&D mission, we are excited to announce that Dr. Shue-Yuan Wang has joined the R&D team as the Director of Cell Line Development with responsibility for mammalian cell line products and services designed for biotherapeutic production. Shue has established a reputation as a thought leader in industrial cell culture and brings significant industry knowledge in therapeutic development through prior roles at Johnson and Johnson, Amgen, Abbott, and Human Genome Sciences. With multiple new kit launches scheduled over the next several years, this focus on industry leading platforms for biotherapeutics will expand GIBCO's future beyond our traditional cell culture media roots.

Win a Countess Automated Cell Counter for your lab!

2010-04-15T12:40:00.000-07:00

To celebrate the success of the Countess® Automated Cell Counter, we are giving away a Countess®, a 16GB iPad with Wi-Fi and a Nintendo Wii 4 in 1 Sport Kit Bundle. Learn more about the contest and how to win any of the prizes by entering the Countess® video contest.

The Countess Automated Cell Counter take the subjectivity and tedium out of one of the fundamental steps of cell culture - counting live and dead cells. With the Countess Automated Cell Counter, producing quality reproducible data is fast and easy. It is also affordable and small, and can easily fit into a lab's budget and workspace. Click here to learn more about the Countess and how it can work for your lab.

No purchase necessary. Submission deadline is May 31, 2010, 11:59 pm PDT. The contest requires min. of 5 video submissions from different entrants. And to win, each submission must receive min. of 500 votes. The complete official rules of entry can be found here after clicking the "enter" tab.

Life Technologies Japan Completes Installation of Japan National Police Agency's 3B Yen Investment to Upgrade Forensic Testing Instrumentation

2010-03-29T17:36:00.000-07:00

TOKYO, Japan – March 25, 2010 – Life Technologies Japan, a subsidiary of Life Technologies Corporation (NASDAQ: LIFE), a provider of innovative life science solutions, today announced that it has completed the installation of DNA analysis software, genetic analyzers, and DNA extraction instrumentation for the National Police Agency (NPA) and its 47 prefectural forensic science laboratories. This installation represents a 3 billion yen (approximately $30M) investment by the NPA to modernize its testing systems in all prefectural police agencies across Japan, and increases their current capabilities to enable high throughput forensic testing. NPA chose Life Technologies’ forensic testing instrumentation because it meets the rigorous requirements to provide the highest quality testing results to law enforcement officers.

“Japan’s recent investment demonstrates a strong commitment to protecting public safety and establishes Japan’s prefectural forensic science laboratories as one of the world’s most sophisticated laboratory systems,” said Leonard Klevan, Ph.D., President of Human Identification at Life Technologies. “This commitment is part of a larger trend in the United States, Europe, China and other countries to utilize the power of DNA databases to share investigative information in order to enhance the criminal process and bring justice to victims worldwide.”

Japan transitioned to a mixed jury system for serious crimes in 2009. This change in the legal system created a need to evaluate a broader scope of evidence and is expected to increase the overall use of DNA in the investigative and legal process. “We expect that the enhanced capacity will accommodate this increasing need for more DNA analysis,” said Siddhartha Kadia, PhD., Chief Operating Officer of Life Technologies Japan. “Life Technologies has been providing leading edge DNA analysis instrumentations for Japan’s police system since the 1990’s. We are committed to ensuring that the latest instrumentation is utilized effectively to provide the highest quality testing results to law enforcement officers. We value the trust that the NRIPS and NPA have in Life Technologies, and will provide our best support as Japan transitions into a new legal system.”

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

About Life Technologies Japan (http://www.lifetech.co.jp/)

Life Technologies Japan is a subsidiary of Life Technologies Corporation. Life Technologies brands are found in more than 90 percent of research laboratories in Japan. The company serves more than 55,000 end-users in Japan, including leading scientists in both academic and commercial life science and biotechnology organizations. Life Technologies Japan employs approximately 350 people.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

For Research Use Only. Not for use in diagnostic procedures.

Life Technologies Japan Contact

Eriko Takahata

+81 30 5566 6563

Eriko.Takahata@lifetech.com

Excite Your Mind!

2010-03-26T14:06:00.000-07:00

The 2010 San Diego Science Festival Expo is tomorrow, Saturday, March 27 at Petco Park. Admission is free and there will be 150 hands-on exhibits and 20 stage performances. Visit the Life Technologies Discovery Stage from 10:30 - 3:30PM where kids can touch science. It's fun for the whole family!

Get the full schedule here.

febit Launches Whole Genome Sequencing Service in Europe

2010-03-23T14:08:00.000-07:00

Yesterday, febit announced that the company offers whole genome sequencing services in Europe for a broad range of species. febit acquired two Applied Biosystems SOLiD™ high-throughput sequencing systems from Life Technologies for whole genome resequencing. One of the two systems will be used within R&D while the other is employed within febit’s Genomic Service Department.

“We combine our expertise in optimizing samples for highest coverage in targeted resequencing with the established SOLiD sequencing power,” said Peer Staehler, CSO of febit.

The complete press release from febit can be read here.

Life Technologies Teams with Gen-Probe to offer Aneuploidy Kits

2010-03-22T09:56:00.000-07:00

Life Technologies Teams with Gen-Probe Life Sciences to Provide Elucigene QST*R Aneuploidy Kits

CARLSBAD, Calif. – March 20, 2010 – Life Technologies Corporation today announced a partnership with Gen-Probe Life Sciences Ltd., to commercialize Gen-Probe’s Elucigene QST*R Aneuploidy Kits under the Applied Biosystems brand in Eastern Europe, Asia, Africa, Australia, Latin America and Canada. The kits will not be available for sale in the U.S.

“Through our collaboration with Gen-Probe Life Sciences, we will be providing diagnostic labs with specialized kits for the rapid and unambiguous analysis of the most common viable human aneuploidies or chromosomal abnormalities, including Down syndrome,” said Andy Felton, Ph. D., Director, Genetic Systems Division at Life Technologies. “By working with Gen-Probe Life Sciences, we take another important step toward our continued commitment to deliver high value diagnostic assays for use in the clinic. This agreement exemplifies Life Technologies’ dedication to deliver easy to use, highly accurate applications on our CE sequencing systems.”

The kits are labeled for use in diagnostics and work in conjunction with the Applied Biosystems industry-leading line of capillary electrophoresis (CE) systems, including the new 3500 Series Genetic Analyzer. Initial sales of the Applied Biosystems branded kits are anticipated to begin mid-year 2010.

“Gen-Probe Life Sciences is pleased to collaborate with Life Technologies in a combined effort to contribute to advancing molecular medicine,” said Mike Webb, General Manager of Elucigene products for Gen-Probe Life Sciences. “This partnership will enable a wider global presence for our technology which we deeply believe helps improve prenatal care.”

“This joint relationship signifies a combined commitment in providing diagnostic tools for clinical applications,” said Scott Higgins, Business Manager for Gen-Probe Life Sciences. “Through its collaboration with Applied Biosystems, Gen-Probe Life Sciences will be able to provide Aneuploidy Detection Kits to a wider international clinical community.”

About Life Technologies (www.lifetechnologies.com)
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit us online at www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Life Technologies Contact
Patty Zamora
760-476-7818
patty.zamora@lifetech.com

When Pigs Fly

2010-03-19T14:32:00.001-07:00

Terminal 2, gate 23

The latest Life Technologies ad has landed at the San Diego International Airport. While waiting for your flight you can get up close and personal with a drosophila fly, a pig, a rainbow and some algea and learn how these seemingly non-scientific creatures and elements are truly impacting science today and helping lead us all to the discoveries of tomorrow.

Life science holds the key to many of the 21st century's greatest challenges and we're doing our part to find the answers.

Lessons from the Pandemic: Influenza A (H1N1) and the Biotech Industry

2010-03-17T10:48:00.000-07:00

One year ago this April, a new and deadly flu emerged in Mexico that would prove to be one of the most pervasive and virulent influenza strains to emerge in 100 years. As we approach the year anniversary of swine flu entering the public lexicon, join BIOCOM as we hear from influenza experts and discuss lessons learned from this pandemic. How did public health agencies from around the world handle the outbreak? How will vaccine production be handled in the future? And what does the biotech industry need to do better to ensure its ability to respond to public health emergencies like this in the future?

Here KPBS health reporter Tom Fudge asks Brain Plew, Head of Public Health at Life Technologies about what the scientific community has learned about H1N1 over the past year, if the virus has changed and the reason for an actual "flu season". Brian and Tom were joined on the panel by the Vice President of Vaccine Research for Vical Inc., Larry R. Smith, Ph.D, and John D. Tamerius, Ph.D, SVP of Clinical and Regulatory Affairs at Quidel Corporation.

This panel took place on March 17th at the La Jolla Hyatt.

Scientists use the SOLiD System for short reads of chicken DNA

2010-03-10T16:12:00.000-08:00

Domestic animals are excellent models for genetic studies of phenotypic evolution and the chicken is no exception. They have evolved genetic adaptations to a new environment, the farm, and have been subjected to strong human-driven selection leading to remarkable phenotypic changes in morphology, physiology and behavior. Identifying the genetic changes underlying these developments provides new insight into general mechanisms by which genetic variation shapes phenotypic diversity.

This week, in the journal Nature, a paper on Whole-genome resequencing of the chicken was published, using Life Technologies' SOLiD System. The paper describes the use of massively parallel sequencing to identify selective sweeps of favorable alleles and candidate mutations that have had a prominent role in the domestication of chickens (Gallus gallus domesticus) and their subsequent specialization into broiler (meat-producing) and layer (egg-producing) chickens. The researchers cited in this paper have generated 44.5-fold coverage of the chicken genome using pools of genomic DNA representing eight different populations of domestic chickens as well as red jungle fowl (Gallus gallus), the major wild ancestor.

The scientists report more than 7,000,000 single nucleotide polymorphisms, almost 1,300 deletions and a number of putative selective sweeps. One of the most striking selective sweeps found in all domestic chickens occurred at the locus for thyroid stimulating hormone receptor (TSHR), which has a pivotal role in metabolic regulation and photoperiod control of reproduction in vertebrates. Several of the selective sweeps detected in broilers overlapped genes associated with growth, appetite and metabolic regulation. The scientists found little evidence that selection for loss-of-function mutations had a prominent role in chicken domestication, but they detected two deletions in coding sequences that they suggest are functionally important. This study has direct application to animal breeding and enhances the importance of the domestic chicken as a model organism for biomedical research.

To read the complete paper, visit here.

Autophagy: Cells Under Stress

2010-03-04T19:02:00.000-08:00

Autophagy, a cell death process that has emerged in the study of disease areas such as cancer, neuro-degeneration and immunological disorders, is challenging to study due to a lack of accurate, sensitive and robust assays, particularly in neurons, stem cells and cancer cells. Life Technologies is introducing the Premo™ LC3-FP kit, which provides researchers for the first time the ability to view this process in live cells. Based on LC3B, a critical component and indicator of autophagy, the new kit combines the selectivity of an LC3B-fluorescent protein (FP) fusion with the transduction efficiency of the 2^nd generation BacMam technology, enabling unambiguous visualization with a simple, one-step protocol. The BacMam LC3B-FP reagent is added to the cells, including neurons and stem cells, incubation takes place overnight for protein expression, allowing researchers to easily image and analyze. For additional information, click here.

SOLiD™ 3 System Used to Sequence Canadian Bull

2010-03-04T14:29:00.000-08:00

In an effort that brings Canada to the forefront of livestock genomics worldwide, scientists at the University of Alberta have just completed the genome sequencing of two types of bulls, one dairy and one beef (pictured below). These are the first animals to have been fully sequenced in Canada. Dr. Stephen Moore and Dr. Paul Stothard of the University of Alberta’s Bovine Genomics Program, in partnership with Life Technologies, have sequenced to a 20 fold coverage these two bulls on the SOLiD™ 3 System.

What does this mean?
Dr. Moore, the leader of the Bovine Genomics Program, said “Having an assembled sequence of the 3 billion DNA bases that constitute the genome of this elite Holstein bull allows the team to study the genetic variations that characterize its performance and to follow their transmission over subsequent generations. Over 4.6 million genetic mutations were detected in the two bulls most of them previously unknown.

This sequencing is significant to the dairy cattle industry because the bull’s genes are likely to make an important contribution to the genetic make-up of future generations. There will also be benefits for the beef industry. Better knowledge of the genetic variation across the breeds will, through better breeding decisions, improve production efficiency, product quality and animal health, and reduce the environmental footprint of beef cattle production.

"The outcome will be that consumers will benefit from the research with more cost effective and healthier products on store shelves,” said Dr. Moore.

What does the future hold?

Whole genome sequencing was enabled through recent advancements in next generation sequencing platforms. The team sequenced the bull's genomes using the SOLiD™ 3 System by Life Technologies which enabled them to complete the work in seven months at a cost of $130,000. The first cow was sequenced in 2009 after four years at a cost of $50 million.

“The SOLiD technology has allowed us to generate high density sequence information in a small number of runs. Combined with the high accuracy of the data it has made the recent sequencing much more effective than was previously possible,” Dr. Moore said in a statement at the University of Alberta.

Click here for more information.

A look behind the curtain at AGBT

2010-02-26T10:06:00.002-08:00

Welcome to the Life Technologies' suite at AGBT. This week we talked about SOLiD 4hq, debuted SOLiD PI and previewed our single molecule sequencing technology. Take a look at some photos from the suite.

This is the SOLiD PI, which will offer researchers a powerful, high-quality and versatile next-generation sequencing system at an attractive price point for every lab running single or multiplexed samples.

This is the SOLiD EZ Bead Enricher, which is one of three tools that make up the SOLiD EZ Bead System. The system incorporates an emulsifier, amplifier and enricher for automated sample processing, which helps reduce time and cost.

The 3500 Genetic Analyzer set the gold standard in capillary electrophoresis.

Here is a link to all our activities at AGBT.

Welcome to AGBT

2010-02-25T11:22:00.000-08:00

Greg Lucier, Chairman and CEO of Life Technologies, gives the opening remarks at the AGBT Welcome Reception on Wednesday, Feb. 24th in Florida. At the AGBT meeting, we debuted the SOLiD PI System.

Life Technologies debuts SOLiD™ PI at AGBT

2010-02-24T14:47:00.000-08:00

Today in Florida at the AGBT Meeting, we announced plans for the Applied Biosystems SOLiD PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide.

Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.

The SOLiD PI System will provide individual researchers and sequencing core laboratories with a cost-effective instrument that will deliver an accuracy level of 99.99 percent.

Members of the media can contact Patty Zamora at 760-476-7818 or click here to read the press release.

Is this the Life Science Century?

2010-02-22T16:14:00.000-08:00

Myrl Weinberg, National Health Council, David Dobbs, NY Times, Ted Buckley, BIO, Rob Atkinson, ITIF, Greg Lucier, LIFE, and Juan Enriquez, Excel Venture Management listen during a dinner hosted by ITIF and United for Medical Research, and supported by the Life Technologies Foundation. The dinner brought journalists, scientists, industry, and policymakers from Capitol Hill and the White House, together to discuss "Is this the Life Science Century?" and its implications for U.S. innovation policy.

Life Technologies Goes to AGBT - Feb. 24-27

2010-02-22T11:16:00.000-08:00

Life Technologies heads to Marco Island, Florida for the 11th annual Advances in Genome Biology and Technology (AGBT) meeting. The AGBT meeting is now widely regarded as the premier scientific forum for capturing information about the latest advances in new DNA sequencing technologies and their applications to diverse areas in biology and biomedical research.

We will be giving a number of talks on topics including Single Molecule Sequencing. Greg Lucier, our Chairman and CEO will be hosting a "Path to Molecular Medicine" luncheon where Kevin McKernan of Life Technologies; Dietrich Stephan of Ignite Institute; Rebecca Leary with Johns Hopkins Kimmel Cancer Center and Kip Miller of Life Technologies will be speaking. News at the meeting will be around SOLiD 4, SOLiD 4hq Systems and SOLiD EZ Bead, PLUS other exciting news that will be announced during the show.

For questions about Life Technologies at AGBT, contact patty.zamora@lifetech.com.

King Tut reunited with his father

2010-02-22T10:13:00.000-08:00

The Discovery Channel aired "King Tut Unwrapped" on Sunday, Feb. 21. The program highlights MiniFiler from Applied Biosystems as the key to unlocking King Tut's lineage, reuniting him with his father.

Watch the clip here: http://bit.ly/9ri8lS

Life Technologies brings the Olympics to San Diego

2010-02-19T09:13:00.000-08:00

Life Technologies is a proud sponsor of NBC 7/39's broadcast of the Vancouver Winter Olympics to San Diego. Check out Daron Rahlves, 3-time Olympian, talking about his quest for gold in freestyle skiing.

Welcome to Life Technologies News & Views

2010-02-19T09:09:00.000-08:00

WELCOME! Thanks for visiting Life Technologies news & views page, we think you'll find it interesting. We plan to post up-to-the-minute information on where the company is, a picture of the week, videos, links to coverage and thoughts from our executive team from time-to-time. Also, look to the right, you'll see an audio player, yes, we're even going to host a radio program. Come, stay a while and check back often.

Questions? email me at kimberly.evans@lifetech.com